SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter

Summit Therapeutics (SMMT) saw price target reductions from Barclays ($18) and Citi ($42) after the FDA issued a complete response letter for its lung cancer treatment, ivonescimab. Barclays noted potential implications for the lung cancer program, while Citi cited the CRL as the reason for its reduction. Jefferies maintained a 'Buy' rating with a $30 target, stating the setback was anticipated. SMMT shares fell 11% following the news.

Original reporting
Published Nov 16, 2026, 3:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SMMT Stock Sees Price Target Reductions – A Look At What Analysts Said About FDA’s Complete Response Letter — source image
Decision brief

The 30-second read

$SMMTBearishHigh
01

Why it matters

Analyst target cuts reflect belief that the regulatory hurdle lowers near‑term valuation, but continued development in other indications may preserve long‑term upside.

02

Market read

The FDA CRL and subsequent analyst target reductions create immediate bearish pressure on SMMT, with potential spill‑over to similar biotech stocks.

03

What to watch

Potential for the drug to succeed in first‑line settings or colorectal cancer could mitigate the impact of this CRL.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Summit Therapeutics is developing ivonescimab for NSCLC; the FDA CRL cites insufficient overall‑survival benefit despite progression‑free survival improvement.

Company-level read

Ticker impact

$SMMTBearishHigh confidence
Context

FDA issued a complete response letter for Summit's ivonescimab lung‑cancer application, prompting analysts to cut price targets and the stock fell 11%.

Expected impact

likely pressure as the market prices in the FDA CRL and lowered analyst targets

Evidence & confidence

The CRL is a material regulatory event for a biotech; analysts have already reduced targets, indicating bearish sentiment.

Market effects

Other lung‑cancer biotech peers may see heightened scrutiny on trial data.

US biotech sector could face short‑term pressure.

Limited to biotech investors; no broad market effect.

Counterpoint

If Summit can demonstrate efficacy in other indications, the stock may rebound on future data.

Key entities

  • Summit Therapeutics

    Biotech firm developing ivonescimab.

  • FDA

    Issued the complete response letter.

Related articles

$SMMTHighAI 9/10

Summit Therapeutics Sinks on FDA Rejection

Summit Therapeutics (SMMT) shares fell 16.5% after the FDA rejected its lung cancer drug ivonescimab, citing insufficient evidence of overall survival benefit. The company plans to continue development, but no resubmission timeline was provided. Summit's stock closed at $11.82, its lowest since August. The FDA's decision follows positive progression-free survival results but insufficient overall survival data.

$SMMTMedAI 8/10

2 Cancer-Drug Developers Seeing Unusual Options Volume

Summit Therapeutics (SMMT) fell 15% to $12.02 after the FDA declined to approve its lung cancer drug, requesting more survival data. Citi cut its price target to $42. CG Oncology (CGON) rose 12.5% to $83.70 after its bladder cancer treatment met trial goals, reducing recurrence risk by 68%. Both saw unusual options activity, with bearish sentiment.

$SMMTHighAI 9/10

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Summit Therapeutics (SMMT) shares fell 20% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient evidence of effectiveness. The drug showed progression-free survival benefits but failed to meet overall survival endpoints. The setback delays U.S. launch plans and creates regulatory uncertainty. Year-to-date, SMMT shares are down 19.1%.

$SMMTHighAI 8/10

Summit Therapeutics tumbles 13% after FDA rejects lung cancer drug application

Summit Therapeutics (SMMT) shares dropped 13% after the FDA rejected its lung cancer drug application, citing insufficient overall survival benefit. The HARMONi trial showed improved progression-free survival but missed the statistical significance threshold for overall survival. Jefferies noted the decision was anticipated and maintained focus on the upcoming HARMONi-3 trial results.